June 27, 2005


A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
+1 (978) 421-9655


Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637


ZOLL Receives Frost & Sullivan's 2005 Product Line Strategy Leadership Award

Monday, June 27, 2005 – CHELMSFORD, MASS.—ZOLL Medical Corporation (NASDAQ: ZOLL), a manufacturer of resuscitation devices and software solutions, announced today it has received Frost & Sullivan’s 2005 Product Line Strategy Leadership Award for the U.S. external defibrillator market. ZOLL received this Award due to recent acquisitions and expansions to its resuscitation product line, coupled with an ability to demonstrate considerable insight into customer needs and product demands.

Frost & Sullivan notes that ZOLL has several novel solutions that can help improve resuscitation efforts by enhancing emergency circulatory support during sudden cardiac arrest, which strikes 450,000 people annually in the U.S. According to Frost & Sullivan Analyst Nathan Cohen, “Later this year, the American Heart Association will update industry guidelines for cardiopulmonary resuscitation (CPR) and defibrillation, and it is expected to increase the focus on early CPR. Additionally, recent studies have reported the low quality of CPR being delivered in hospital and pre-hospital settings. By including real-time feedback on circulatory support in its line of products, ZOLL will not only improve its sales, but the company is prepared and positioned well to help revolutionize the quality and effectiveness of resuscitation in the healthcare industry.”

“We believe that ZOLL has had remarkable success in the external defibrillator market in the face of strong competition,” said Richard A. Packer, President and Chief Executive Officer. “As a company, we have been focused on external defibrillation, which has been a key strength. We are now at a time in our company’s history where we can take that strength and broaden our reach to other areas of resuscitation. While providing industry leadership in this area takes significant investment, we believe it will pay big dividends in future growth.”

Mr. Packer continued, “In many cases, the defibrillator was seen as the only device needed to solve the problem of improving survival from sudden cardiac arrest. However, as automated external defibrillators (AEDs) moved into the marketplace, data have shown that less than half of the people connected to an AED require an immediate defibrillating shock. The majority of the people need other therapies, in addition to defibrillation, to give them a reasonable chance of survival. Circulatory support, ventilation, and documentation and data management are all examples of technology needed to improve resuscitation outcomes. This Frost & Sullivan Award brings additional credence to our vision of improving the practice of resuscitation.”

Frost & Sullivan made its selection based upon the following criteria:
• Introduction of new products, strategically positioned to balance the product line;
• Ability to accommodate different market segments, or different markets within an industry by repurposing technology;
• Enhancement of product offerings through optimization of packaging, service, delivery, financing, and/or other value-added services; and
• Strategic technology or marketing acquisitions or alliances.

ZOLL has several products that provide rescuers with instantaneous feedback on the rate and depth of CPR chest compressions, which can help address emergency circulatory support during CPR. These products include the AED Plus,™ which is an AED designed for infrequent rescuers and first-responders, as well as the AED Pro,™ which was launched in 2004 for professional rescuers. Additionally, the ZOLL AutoPulse™ Non-invasive Cardiac Support Pump provides automated chest compressions in a unique, consistent “hands-free” manner. The AutoPulse offers the promise of circulating more blood to the heart and brain.(1-5) The automated, portable device is comprised of a backboard and a simple LifeBand™ that fastens across a victim’s chest.

About Frost & Sullivan

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company’s industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.

About ZOLL Medical Corporation

ZOLL Medical Corporation (NASDAQ: ZOLL) is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation, ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies that can help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical data.

ZOLL has operations in the United States, Canada, the United Kingdom, Germany, France, The Netherlands, Australia, and Austria. With direct operations, international offices, and business partners in all of the world’s major markets, ZOLL markets and sells its products in more than 140 countries.

Certain statements contained in this press release, including statements regarding the anticipated development of ZOLL’s business, potential sales levels, its ability to differentiate its products from others on the market, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to the ability of the ZOLL sales force to market successfully multiple resuscitation products, and those factors discussed in the section entitled “Risk Factors” in ZOLL’s Quarterly Report on Form 10-Q, which was filed with the SEC on May 13, 2005.

To learn more about this award:

# # #

Copyright © 2005 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. AutoPulse and LifeBand are trademarks of ZOLL Medical Corporation. Power Infuser and ZOLL are registered trademarks of ZOLL Medical Corporation. All trademarks are property of their respective owners.

1 Casner M et al. The impact of a new CPR assist device on rate of return of spontaneous circulation in out-of-hospital cardiac arrest. Prehospital Emergency Care. 2005;9:61-67.
2 Timerman S et al. Improved hemodynamic performance with a novel chest compression device during treatment of in-hospital cardiac arrest. Resuscitation. 2004;61:273-280.
3 Halperin HR et al. Improved hemodynamics with a novel chest compression device during a porcine model of cardiac arrest. Circulation. 2002:106(19)(Suppl II):538.
4 Ikeno F et all. Improved survival with a novel chest compression device during a porcine model of cardiac arrest. Circulation. 2003;108(17)(Suppl IV):381.
5 Ornato JP et al. Improvement in field return of spontaneous circulation using circumferential chest compression cardiopulmonary resuscitation. Prehospital Emergency Care. 9(1):104.